As another example, the interaction between CD47 on cancer cells and SIRPα on macrophages was identified as a key axis enabling tumors to avoid phagocytosis [64]; trials are now testing anti-CD47 agents to enhance macrophage attack on cancer cells, essentially removing a brake on a cell-cell interaction to stimulate immunity. The gene discussed is SIRPA; the disease is cancer.